Resurrecting clinical pharmacology as a context for Alzheimer disease drug development

Curr Alzheimer Res. 2009 Feb;6(1):79-81. doi: 10.2174/156720509787313916.

Abstract

Commercial priorities have been identified as negative factors in drug development. We trace the problem to inattention to sound clinical pharmacology practices. When properly applied, clinical pharmacology and associated drug development sciences can, hand in hand, facilitate success in commercial drug development.

Publication types

  • Comment
  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Acetylcholinesterase / metabolism
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / physiopathology
  • Animals
  • Cholinesterase Inhibitors / administration & dosage
  • Cholinesterase Inhibitors / pharmacology
  • Clinical Trials as Topic / methods*
  • Clinical Trials as Topic / standards
  • Dose-Response Relationship, Drug
  • Drug Industry / methods*
  • Drug Industry / standards
  • Drug-Related Side Effects and Adverse Reactions
  • Humans
  • Pharmacology, Clinical / methods*
  • Pharmacology, Clinical / standards
  • Trichlorfon / administration & dosage
  • Trichlorfon / pharmacology

Substances

  • Cholinesterase Inhibitors
  • Trichlorfon
  • Acetylcholinesterase